Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FMS-like Tyrosine Kinase-3 (FLT3) Mutations”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Not applicableUnknownNCT05596968
What this trial is testing

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793478
What this trial is testing

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 65
Large-scale testing (Phase 3)Not Yet RecruitingNCT05876832
What this trial is testing

XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 312
Large-scale testing (Phase 3)Active Not RecruitingNCT03182244
What this trial is testing

ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Who this might be right for
AML With FLT3 Mutation
Astellas Pharma Inc 276
Not applicableStudy completedNCT03047083
What this trial is testing

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Who this might be right for
Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc. 1,027
Not applicableAvailableNCT03620318
What this trial is testing

Individual Patient Compassionate Use of Crenolanib

Who this might be right for
FLT3-ITD MutationFLT3/TKD MutationPDGFR-Alpha D842V+1 more
Arog Pharmaceuticals, Inc.
Not applicableUnknownNCT05596981
What this trial is testing

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 60
Not applicableApproved For MarketingNCT03070093
What this trial is testing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Not applicableNo Longer AvailableNCT03409081
What this trial is testing

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04240002
What this trial is testing

Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Astellas Pharma Global Development, Inc. 9
Not applicableStudy completedNCT04691648
What this trial is testing

Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Who this might be right for
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Korea, Inc. 33